Flupirtine: pharmacology and clinical applications of a nonopioid analgesic and potentially neuroprotective compound

Bibliography

• Nickel B, Herz A, Jakovlev V, Tibes U. Mechanism of action of the analgesic flupirtine. Arzneimittelforschung 1985;35(9):1402-9
   PubMed Web of Science ®Google Scholar
• Nickel B. The antinociceptive activity of flupirtine: a structurally new analgesic. Postgrad Med J 1987;63(Suppl 3):19-28
   PubMedGoogle Scholar
• Nickel B, Jakovlev V, Szelenyi I. The effect of flupirtine, various analgesics and muscle relaxants on skeletal muscle tone in the conscious rat. Arzneimittelforschung 1990;40(8):909-11 [in German]
   PubMed Web of Science ®Google Scholar
• Szelenyi I, Nickel B. Pharmacological profile of flupirtine, a novel centrally acting, non-opioid analgesic drug. Agents Actions Suppl 1991;32:119-23
   PubMedGoogle Scholar
• Darius H, Schrör K. The action of flupirtine on prostaglandin formation and platelet aggregation in vitro. Arzneimittelforschung 1985;35(1):55-9
   PubMed Web of Science ®Google Scholar
• Block F, Pergande G, Schwarz M. Flupirtine protects against ischaemic retinal dysfunction in rats. Neuroreport 1994;5(18):2630-2
   PubMed Web of Science ®Google Scholar
• Rupalla K, Cao W, Krieglstein J. Flupirtine protects neurons against excitotoxic or ischemic damage and inhibits the increase in cytosolic Ca2+ concentration. Eur J Pharmacol 1995;294(2-3):469-73
   PubMed Web of Science ®Google Scholar
• Perovic S, Schleger C, Pergande G, et al. The triaminopyridine flupirtine prevents cell death in rat cortical cells induced by N-methyl-D-aspartate and gp120 of HIV-1. Eur J Pharmacol 1994;288(1):27-33
   PubMed Web of Science ®Google Scholar
• Osborne NN, Cazevieille C, Wood JP, et al. Flupirtine, a nonopioid centrally acting analgesic, acts as an NMDA antagonist. Gen Pharmacol 1998;30(3):255-63
   PubMedGoogle Scholar
• Schwarz M, Schmitt T, Pergande G, Block F. N-methyl-D-aspartate and alpha 2-adrenergic mechanisms are involved in the depressant action of flupirtine on spinal reflexes in rats. Eur J Pharmacol 1995;276(3):247-55
   PubMed Web of Science ®Google Scholar
• Kornhuber J, Bleich S, Wiltfang J, et al. Flupirtine shows functional NMDA receptor antagonism by enhancing Mg2+ block via activation of voltage independent potassium channels. Rapid communication. J Neural Transm 1999;106(9-10):857-67
   PubMed Web of Science ®Google Scholar
• Jakob R, Krieglstein J. Influence of flupirtine on a G-protein coupled inwardly rectifying potassium current in hippocampal neurones. Br J Pharmacol 1997;122(7):1333-8
   PubMed Web of Science ®Google Scholar
• Stanfield PR, Nakajima Y, Yamaguchi K. Substance P raises neuronal membrane excitability by reducing inward rectification. Nature 1985;315(6019):498-501
   PubMed Web of Science ®Google Scholar
• Sheridan PH, Seaman CA, Narang PK, et al. Pilot study of flupirtine in refractory seizures. Neurology1986;36(Suppl 1)
   Google Scholar
• Gribkoff VK. The therapeutic potential of neuronal KCNQ channel modulators. Expert Opin Ther Targets 2003;7(6):737-48
   PubMed Web of Science ®Google Scholar
• Brown DA, Passmore GM. Neural KCNQ (Kv7) channels. Br J Pharmacol 2009 [Epub ahead of print]
   Google Scholar
• Martire M, Castaldo P, D'Amico M, et al. Mchannels containing KCNQ2 subunits modulate norepinephrine, aspartate, and GABA release from hippocampal nerve terminals. J Neurosci 2004;24(3):592-7
   PubMed Web of Science ®Google Scholar
• Mackie AR, Brueggemann LI, Henderson KK, et al. Vascular KCNQ potassium channels as novel targets for the control of mesenteric artery constriction by vasopressin, based on studies in single cells, pressured arteries, and in vivo measurements of mesenteric vascular resistance. J Pharmacol Exp Ther 2008;325(2):475-83
   PubMed Web of Science ®Google Scholar
• Wladyka CL, Kunze DL. KCNQ/M currents contribute to the resting membrane potential in rat visceral sensory neurons. J Physiol 2006;575(Pt1):175-89
   PubMed Web of Science ®Google Scholar
• Yeung SY, Pucovsky V, Moffatt JD, et al. Molecular expression and pharmacological identification of a role for K(v)7 channels in murine vascular reactivity. Br J Pharmacol 2007;151(6):758-70
   PubMed Web of Science ®Google Scholar
• Blackburn-Munro G, Dalby-Brown W, Mirza NR, et al. Retigabine: chemical synthesis to clinical application. CNS Drug Rev 2005 Spring;11(1):1-20
   PubMedGoogle Scholar
• Obermeier K, Niebch G, Thiemer K. Pharmacokinetics and biotransformation of the analgesic flupirtine in the rat and dog. Arzneimittelforschung 1985;35(1):60-7
   PubMed Web of Science ®Google Scholar
• Hlavica P, Niebch G. Pharmacokinetics and biotransformation of the analgesic flupirtine in humans. Arzneimittelforschung 1985;35(1):67-74
   PubMed Web of Science ®Google Scholar
• Methling K, Reszka P, Lalk M, et al. Investigation of the in vitro metabolism of the analgesic flupirtine. Drug Metab Dispos 2009;37(3):479-93 [Epub 2008 Dec 12]
   PubMed Web of Science ®Google Scholar
• Abrams SM, Baker LR, Crome P, et al. Pharmacokinetics of flupirtine in elderly volunteers and in patients with moderate renal impairment. Postgrad Med J 1988;64(751):361-3
   PubMed Web of Science ®Google Scholar
• Moore RA, Bullingham RE, Simpson S, et al. Comparison of flupirtine maleate and dihydrocodeine in patients following surgery. Br J Anaesth 1983;55(5):429-32
   PubMed Web of Science ®Google Scholar
• Galasko CS, Courtenay PM, Jane M, Stamp TC. Trial of oral flupirtine maleate in the treatment of pain after orthopaedic surgery. Curr Med Res Opin 1985;9(9):594-601
   PubMed Web of Science ®Google Scholar
• Mastronardi P, D'Onofrio M, Scanni E, et al. Analgesic activity of flupirtine maleate: a controlled double-blind study with diclofenac sodium in orthopaedics. J Int Med Res 1988 Sep-Oct;16(5):338-48. J Int Med Res 1988;16(5):338-48
   PubMed Web of Science ®Google Scholar
• Scheef W. Analgesic efficacy and safety of oral flupirtine in the treatment of cancer pain. Postgrad Med J 1987;63(Suppl 3):67-70
   PubMed Web of Science ®Google Scholar
• Heusinger JH. Efficacy and tolerance of flupirtine and pentazocine in two multicentre trials. Postgrad Med J 1987;63(Suppl 3):71-9
   PubMedGoogle Scholar
• Lüben V, Müller H, Lobisch M, Wörz R. Treatment of tumor pain with flupirtine. Results of a double-blind study versus tramadol. Fortschr Med 1994;112(19):282-6
   PubMedGoogle Scholar
• Million R, Finlay BR, Whittington JR. Clinical trial of flupirtine maleate in patients with migraine. Curr Med Res Opin 1984;9(3):204-12
   PubMed Web of Science ®Google Scholar
• Wörz R. Flupirtine in chronic myofacial pain conditions. Fortschr Med 1991;109(6):158-60
   PubMedGoogle Scholar
• Ringe JD, Miethe D, Pittrow D, Wegscheider K. Analgesic efficacy of flupirtine in primary care of patients with osteoporosis related pain. A multivariate analysis. Arzneimittelforschung 2003;53(7):496-502
   PubMed Web of Science ®Google Scholar
• Müller-Schwefe GH, Uberall MA. Analgesic and muscle tonus normalizing effect of flupirtine retard in chronic back pain. Results of a standardized therapeutic evaluation applying objective methods for measuring pain pressure threshold, pain pressure tolerance and muscle tension. MMW Fortschr Med 2008;149(Suppl 4):153-61
   PubMedGoogle Scholar
• Li C, Ni J, Wang Z, et al. Analgesic efficacy and tolerability of flupirtine vs. tramadol in patients with subacute low back pain: a double-blind multicentre trial. Curr Med Res Opin 2008;24(12):3523-30
   PubMed Web of Science ®Google Scholar
• Göbel H, Schmid J, Heinze A, Pergande G. Reduction of spastic increased muscle tone in multiple sclerosis by the nonopioid analgesic flupirtine. Schmerz 1999;13(5):324-31
   PubMed Web of Science ®Google Scholar
• Schwarz M, Nolden-Koch M, Purr J, et al. Antiparkinsonian effect of flupirtine in monoamine-depleted rats. J Neural Transm 1996;103(5):581-90
   PubMed Web of Science ®Google Scholar
• Schmidt WJ, Schuster G, Wacker E, Pergande G. Antiparkinsonian and other motor effects of flupirtine alone and in combination with dopaminergic drugs. Eur J Pharmacol 1997;327(1):1-9
   PubMed Web of Science ®Google Scholar
• Putzki N, Maschke M, Drepper J, et al. Effect of functional NMDA-antagonist flupirtine on automatic postural responses in Parkinson's disease. J Neurol 2002;249(7):824-8
   PubMed Web of Science ®Google Scholar
• Sättler MB, Williams SK, Neusch C, et al. Flupirtine as neuroprotective add-on therapy in autoimmune optic neuritis. Am J Pathol 2008;173(5):1496-507
   PubMed Web of Science ®Google Scholar
• Boscia F, Annunziato L, Taglialatela M. Retigabine and flupirtine exert neuroprotective actions in organotypic hippocampal cultures. Neuropharmacology 2006;51(2):283-94
   PubMed Web of Science ®Google Scholar
• Dhar S, Bitting RL, Rylova SN, et al. Flupirtine blocks apoptosis in batten patient lymphoblasts and in human postmitotic CLN3- and CLN2-deficient neurons. Ann Neurol 2002;51(4):448-66
   PubMed Web of Science ®Google Scholar
• Otto M, Cepek L, Ratzka P, et al. Efficacy of flupirtine on cognitive function in patients with CJD: a double-blind study. Neurology 2004;62(5):714-8
   PubMed Web of Science ®Google Scholar